MultiMedica Scientific Research


Study and development of new pro- and prebiotic products for the prevention and treatment of dysmetabolism (PROBIOTIKÀ)

The PROBIOTIKA’ project represents the first nucleus of business aggregation for the creation of a HUB dedicated to the research, development and industrialization of innovative probiotic products and to the study of new nutraceuticals able to prevent and reduce serious dysmetabolisms linked to microbiota imbalances due to antibiotic therapies.

Probiotiká’s activities have focused on:

1) Study and characterization of new pro and prebiotic products for the control of hypercholesterolemia.

  • Study of a new blend of Saccharomyces Cerevisiae (Boulardii variety), dry extract of garlic and vitamin B6, useful to support the reduction of blood cholesterol levels.
  • Development of nutraceutical foods derived from the processing of fruit and vegetables, chocolates, pralines, biscuits with special flours (spelt/potatoes) and also with truffles, in which the probiotic charge survives for 24 months at room temperature. The first results of the in vivo trial of the mix, showed a 10% reduction in plasma cholesterol levels after 90 days of intake.
  • Development of a new product consisting of Clausii and Saccharomyces Boulardii probiotics, prebiotics and vitamins, in order to evaluate the lowering of blood cholesterol levels and to verify the efficacy on the reference macrobiota.
  • A strain of Lactobacillus Reuteri has been isolated and characterized that metabolizes BSHase (Bile salts Hydrolase) 5 to 10% faster.

2) Study and characterization of new pro- and prebiotic products for the control of dysmetabolisms related to human microbiota alterations.

  • Development of alternative formulations with B.Clausii and raw materials at the base of lactive in solid form: a concentration of B.Clausii equal to 6 billion per sachet (the concentration ounces per day for the adult) has been reached in combination with lactoferrin, pepsin, lime, green tea, red grape extract and other excipients able to guarantee a good palatability and dispersion.
  • A test was performed on 700 free living subjects for microbiota analysis. The results allowed to identify a series of taxa associated with the typical characteristics of dyslipidemia and cardiovascular diseases (CV). Two new taxa were identified for CV diseases, Chorobacteriaceae and Shigella, which have never been reported before, and their species correlating with the presence of CV disease and metabolic syndrome pattern.